|
|
![]() |
|
METHODOLOGY / PROCEDURE
FOR PRICE As per par 3 of DPCO, 1995
prices of scheduled bulk drugs are fixed by the NPPA to make them available
at a fair price from different manufacturers. These prices are fixed
from time to time by notification in official gazette.
Following steps are
involved in fixation/revision of bulk drug prices :-
Step 1 : Identification
of bulk drugs :
Bulk Drugs are taken up
for study on following basis :-
Step 2 : Collection of data : Data is collected by issuing questionnaire/Form
I of DPCO, 1995/cost-audit report etc. and verification by plant visits,
if required. Step 3 : Preparation
of actual cost statement : Actual cost for the year for
which data is submitted is prepared based on data submitted / collected
& verified during plant visit. Step 4 : Preparation
of Technical Parameters : Technical parameters are prepared
based on data submitted, collected and verified during plant visits.
Plant capacity is assessed considering 330 working days for normal operation
of plant leaving 35 days for scheduled maintenance of plant. The achievable
production level is considered at 90% utilisation of assessed capacity
allowing 10% production loss on account of unforseen break down and
non-scheduled maintenance. Step 5 : Preparation
of Estimated Cost : The estimated cost for the
pricing period are then prepared based on actual cost & the technical
parameters. While projecting the future cost, an increment is recognised
at 5% per annum in respect of salaries & wages. Wage agreement, if any,
which has been finalised and signed is also recognised while preparing
the estimates. In respect of other overheads of fixed/semi variable
nature, increase at 2.5% per annum is made to cover the normal incremental
effects. The customs duty and other taxes as per the current budget
are considered. Step 6 : Calculation
of Fair price of bulk drug : Fair price is calculated by
providing returns as specified in sub para (2), para 3 of DPCO, 1995. While fixing the maximum sale
price of the bulk drug, a post tax return of 14% on networth or a return
of 22% of capital employed or in respect of a new plant an internal
rate of return of 12% based on long term marginal costing is considered
depending upon the option exercised by the manufacturer of the bulk
drug. In case, the production is from basic stage, additional 4% return
is considered on net worth/capital employed. Step 7 : Fixation
of maximum sale price of the drug : When the number of manufacturers
of the said drug is more than one, the maximum sale price is fixed at
2/3rd cut off level or weighted average price, depending upon the situation. Step 8 : Notification
of bulk drug price in official Gazette. Note : The
fair price may be further revised, if asked for by the manufacturers,
based on escalation formula for change in major raw materials and utilities
rates. |